Physician profile
Marlee Booty
NPI 1306445069
$7,519.73
in general payments reported to CMS, 2019-2025
62 companies · $2,980 in 2025
The $2,980 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $2,259 · 2024: $2,043 · 2025: $2,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,760 · Education: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,759.85 |
| Education | $522.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $562.25 | 2022-2025 | Erleada, Darzalex, Talvey |
| Pfizer INC. | $506.04 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $474.84 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $455.89 | 2023-2025 | Enhertu, Lynparza, Imfinzi |
| Incyte Corporation | $409.43 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $368.55 | 2023-2025 | |
| Astellas Pharma US INC | $269.18 | 2023-2025 | Xtandi, Vyloy, Padcev |
| Genmab U.S., INC. | $240.33 | 2023-2025 | Epkinly, Tivdak |
| Beigene USA, INC. | $223.99 | 2023-2025 | Brukinsa, Tevimbra |
| Pharmacosmos Therapeutics INC. | $212.26 | 2022-2024 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $207.35 | 2022-2025 | |
| Celgene Corporation | $202.33 | 2023-2025 | Reblozyl, Opdualag |
| Gilead Sciences, INC. | $198.03 | 2023-2025 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $191.47 | 2023-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $170.87 | 2022-2025 | Opdivo, Reblozyl |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $156.58 | 2023-2025 | Venclexta, Polivy |
| Array Biopharma INC | $149.62 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Adaptive Biotechnologies Corporation | $142.52 | 2023-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $121.38 | 2023-2025 | Libtayo |
| Puma Biotechnology, INC. | $119.83 | 2022-2025 | |
| Eisai INC. | $118.16 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $116.07 | 2022-2024 | |
| Lilly USA, LLC | $101.31 | 2023-2025 | Jaypirca, Verzenio |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $93.52 | 2024-2025 | Somatuline Depot, Onivyde, Tazverik |
| Genzyme Corporation | $87.65 | 2023-2025 | |
| Glaxosmithkline, LLC. | $87.60 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Abbvie INC. | $87.25 | 2024-2025 | |
| Daiichi Sankyo INC. | $85.33 | 2022-2025 | Datroway, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $83.07 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Seagen INC. | $82.34 | 2022-2023 | Adcetris, Tukysa |
| Beone Medicines USA, INC. | $79.63 | 2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $71.43 | 2023-2025 | Cabometyx |
| Stemline Therapeutics INC. | $70.68 | 2024-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $60.15 | 2023-2025 | Xpovio |
| Morphosys, US INC. | $56.88 | 2022-2023 | Monjuvi |
| Pharmaessentia USA Corporation | $52.58 | 2023-2024 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.43 | 2024-2025 | Gilotrif |
| Geron Corporation | $44.07 | 2025 | Rytelo |
| Dendreon Pharmaceuticals LLC | $43.74 | 2025 | Provenge |
| Coherus Oncology, INC. | $38.92 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $36.18 | 2023 | Givlaari |
| Amgen INC. | $35.47 | 2023 | Lumakras |
| Mirati Therapeutics, INC. | $33.65 | 2024 | Krazati |
| Cumberland Pharmaceuticals, INC. | $32.15 | 2024-2025 | Sancuso |
| Spectrum Pharmaceuticals INC. | $32.10 | 2024 | Rolvedon |
| Adc Therapeutics America, INC. | $31.35 | 2023 | |
| Shield Therapeutics INC | $31.20 | 2024 | |
| Progenics Pharmaceuticals, INC. | $30.84 | 2023 | Pylarify |
| Tolmar, INC. | $29.41 | 2023-2025 | Eligard, Rubraca |
| Emd Serono, INC. | $26.84 | 2023-2024 | Bavencio |
| Pharmaand Gmbh | $24.36 | 2025 | Rubraca |
| Servier Pharmaceuticals LLC | $23.13 | 2025 | |
| Rigel Pharmaceuticals, INC. | $21.48 | 2023 | Rezlidhia, Tavalisse |
| Sobi, INC | $21.15 | 2024 | |
| Azurity Pharmaceuticals, INC. | $20.43 | 2025 | Danziten |
| Celltrion USA INC. | $19.30 | 2025 | Vegzelma |
| Fresenius Kabi USA, LLC | $18.91 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.51 | 2023 | Xarelto |
| Caris Mpi, INC. | $16.00 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $13.96 | 2025 | Yescarta |
| Ferring Pharmaceuticals INC. | $13.76 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlee Booty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.